All In Biotech

Drug Trial Radar · NCT06988488

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

62

Planned (sponsor's estimate)

Start

Oct 7, 2025

Primary completion

May 31, 2027

Study completion Jun 3, 2027

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • ElranatamabDrug

    Specified dose on specified days

  • MezigdomideDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
  2. Number of participants with Serious AEsTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
  3. Number of participants with AEs meeting protocol-defined DLT criteriaTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
  4. Number of participants with AEs leading to discontinuationTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
  5. Number of deathsTime frame: From first participant first visit until 28 days after the last mezigdomide dose or 90 days after last elranatamab dose, whichever is longer
  6. Recommended Phase 2 Dose (RP2D)Time frame: From first participant enrollment until the last participant is no longer evaluable for response or has progressed or the last survival follow-up (At approximately 5 years)

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Yale New Haven Hospital-Smilow Cancer Center

    New Haven, Connecticut · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada · Recruiting

  • Local Institution - 0026

    Vancouver, British Columbia, Canada · Not yet recruiting

  • QEII Health Sciences Centre - Victoria General Site

    Halifax, Nova Scotia, Canada · Recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • Local Institution - 0030

    Suzhou, Jiangsu, China · Not yet recruiting

  • Tongji University - Shanghai Fourth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, Germany · Recruiting

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, Germany · Recruiting

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany · Recruiting

  • Evangelismos General Hospital of Athens

    Athens, Attikí, Greece · Recruiting

  • Alexandra General Hospital of Athens

    Athens, Attikí, Greece · Recruiting

  • Sykehusapoteket Ull

    Oslo, Norway · Recruiting

  • St. Olavs Hospital

    Trondheim, Sør-Trøndelag, Norway · Recruiting

  • Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca

    Salamanca, Spain · Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, Spain · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom · Recruiting

  • University College London Hospital

    London, England, United Kingdom · Recruiting

  • Royal Marsden Hospital (Sutton)

    London, Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.